Marina Biotech, Inc. (OTCMKTS:MRNA) traded up 9.7% during trading on Thursday . The stock traded as high as $17.48 and last traded at $16.60. 2,256,738 shares changed hands during trading, an increase of 131% from the average session volume of 978,135 shares. The stock had previously closed at $15.13.
Several research firms have recently commented on MRNA. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Marina Biotech in a research note on Thursday, January 10th. Oppenheimer initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They issued an “outperform” rating and a $27.00 price objective on the stock. Morgan Stanley initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set an “overweight” rating and a $29.00 target price on the stock. Needham & Company LLC initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set a “buy” rating and a $28.00 target price on the stock. Finally, Barclays initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set an “overweight” rating and a $20.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $24.38.
TRADEMARK VIOLATION WARNING: “Marina Biotech (MRNA) Trading 9.7% Higher” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4116325/marina-biotech-mrna-trading-9-7-higher.html.
Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.
Read More: What is the quiet period?
Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.